News & Updates

For young children with an upper respiratory tract infection, also known as common cold, treatment with hypertonic saline nasal drops is safe and beneficial, shortening recovery time by 2 days and, in turn, reducing household spread of the disease, according to the results of the ELVIS-Kids trial.

Treatment with dupilumab reduced airway mucus plug scores and volume in patients with uncontrolled, moderate-to-severe asthma, according to the phase IV VESTIGE trial presented at ERS 2024.

New drug applications approved by US FDA as of 16-31 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Nirmatrelvir-ritonavir has emerged as a key antiviral therapy in the fight against COVID-19, particularly for high-risk populations. Two recently published studies demonstrated the efficacy of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and in those with advanced kidney disease.

Tablet 500 mg/25 mg/2 mg

Capsule 325 mg/25 mg/10 mg

The ENVIE* study demonstrates the real-world effectiveness of nirsevimab against hospitalization for bronchiolitis associated with respiratory syncytial virus (RSV) among infants <12 months of age in France.